Dupilumab in Adults With Moderate to Severe Atopic DermatitisLisa A. Beck, Arsalan Shabbir, Robert Bissonnette et al.|JAMA Dermatology|2024Cited by 64
Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trialsYoshiya Tanaka, Hideto Kameda, Toshiya Takahashi et al.|Modern Rheumatology|2021Cited by 5
Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults With Moderate-to-Severe Atopic Dermatitis: An Analysis of a Randomized, Double-Blind Phase III StudyYan Zhao, Liming Wu, Qianjin Lu et al.|International Journal of Dermatology and Venereology|2022Cited by 4
Pharmacokinetics, pharmacodynamics, and safety of single-dose subcutaneous sarilumab with or without methotrexate in Japanese patients with rheumatoid arthritis: Two single-dose studiesTomonori Ishii, Toshiya Takahashi, Yukio Sato et al.|Modern Rheumatology|2022Cited by 1